repurposing
Drug repurposing allows a reconciliation of the time of research with the one of medicine in order to meet the high medical need
Drug screening
Screening of thousand molecules helps in identifying drug candidates for patients and potential new therapeutic targets.
development
The development of approved molecule is facilitated by the available knowledge produced by the former developments.
APTEEUS has developed unique know-how and technology dedicated to drug discovery and repositioning. We are interested in pathologies for which the medical need is important and largely unsatisfied, particularly rare monogenic diseases. Our technology allows us to carry out discovery projects in a few months, and to identify new drug candidates. We work in collaboration with patient associations, doctors and academic and industrial partners. Our activity breaks with the classic drug discovery scheme and aims for a rapid and significant social impact.
OUR TΞCHNOLOGY
Operando®
OPERANDO is the biomedical research program in place for collecting cutaneous biopsies from patients in order to isolate the cells “model” of the pathology.
evidenceFactory®
evidenceFactory is the processes we use to measure, in vitro, the causal defects of the symptoms. Based on cell imaging and mass spectrometry, they are systematically miniaturized and automated to quickly test several thousand molecules.
TEE Library®
TEE Library is our proprietary collection of molecules approved for human use and enriched daily that we test in every new screen.
NΞWs
15th edition of the Rare Disease Day
On the occasion of the 15th edition of the Rare Diseases awareness campaign which took…
The beginning of clofoctol story in covid19
You will read why we decided to run clinical trials with clofoctol in covid19… Large…
HERE WE ARE, THE CLOFOCTOL TRIAL IN COVID19 WILL BEGIN!
The entire Apteeus team is delighted with this news. After months of fundraising, designing the…
LEADΞRSHIP
Dr. Terence Beghyn
Pharm.D & PhD in Medicinal Chemistry
Passionate about drug discovery technologies, Terence co-founded Apteeus to put his expertise to work for patients with orphan diseases. Terence is President of the company Apteeus.
Professor Benoit DEPREZ
Professor of Pharmacy
Benoit began his career in two biotech companies by leading the chemistry and drug discovery teams. Returning to the University in 2006, he set up a drug discovery laboratory at the Institut Pasteur de Lille, which was labelled by INSERM. Benoit is Scientific Director of the Institut Pasteur de Lille. He co-founded Apteeus and is strategic advisor.
partners
